Severe Hemophilia A clinical trials

Explore recruiting severe hemophilia a clinical trials.

Recruiting severe hemophilia a studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Severe Hemophilia A trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

(21824) A phase 3, single group treatment, open-label study to evaluate the safety of BAY 94-9027 infusions for prophylaxis and treatment of bleeding in previously treated children aged 7 to <12 years with severe hemophilia A

Norway, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

ATLAS-PEDS: An open-label, multinational study of fitusiran prophylaxis in pediatric subjects ages 1 to less than 12 years with hemophilia A or B

Italy, Spain

Phase II and Phase III (Integrated) EU CTIS Study details

C3731003 Phase 3, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of PF-07055480 (Recombinant AAV2/6 Human Factor VIII Gene Therapy) in Adult Male Participants with Moderately Severe to Severe Hemophilia A (FVIII:C≤1%)

Germany, Spain, France, Greece, Sweden

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)

Spain, Germany, Belgium, Italy, France, Poland +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

(19429) A phase 1/2 open-label safety and dose-finding study of BAY 2599023 (DTX201), an adeno-associated virus (AAV) hu37-mediated gene transfer of B-domain deleted human factor VIII, in adults with severe hemophilia A

Netherlands, Germany, France, Bulgaria

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Emicizumab in Patients with Mild or Moderate Hemophilia A without FVIII Inhibitors

Germany, France, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

Severe Hemophilia A trials by city

Severe Hemophilia A in Toronto Severe Hemophilia A in Vancouver Severe Hemophilia A in Montreal Severe Hemophilia A in Calgary Severe Hemophilia A in Edmonton Severe Hemophilia A in Ottawa Severe Hemophilia A in Winnipeg Severe Hemophilia A in Quebec City Severe Hemophilia A in Hamilton Severe Hemophilia A in Kitchener Severe Hemophilia A in London Severe Hemophilia A in Halifax Severe Hemophilia A in New York Severe Hemophilia A in Los Angeles Severe Hemophilia A in Chicago Severe Hemophilia A in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease